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Abstract
Background—Health systems may play an important role in identification of patients at-risk of 
opioid medication overdose. However, standard measures for identifying overdose risk in 
administrative data do not exist.
Objective—Examine the association between opioid medication overdose and 2 validated 
measures of non-medical use of prescription opioids within claims data.
Research Design—A longitudinal retrospective cohort study that estimated associations 
between overdose and non-medical use.
Subjects—Adult Pennsylvania Medicaid program 2007-2012 patients initiating opioid treatment 
who were: non-dual eligible, without cancer diagnosis, and not in long-term care facilities or 
receiving hospice.
Measures—Overdose (International Classification of Disease, 9th edition, prescription opioid 
poisonings codes), opioid abuse (opioid use disorder diagnosis while possessing an opioid 
prescription), opioid misuse (a composite indicator of number of opioid prescribers, number of 
pharmacies, and days supplied), and dose exposure during opioid treatment episodes.
Results—A total of 372,347 Medicaid enrollees with 583,013 new opioid treatment episodes 
were included in the cohort. Opioid overdose was higher among those with abuse (1.5%) 
compared to those without (0.2%, p<0.001). Overdose was higher among those with probable 
(1.8%) and possible (0.9%) misuse compared to those without (0.2%, p<0.001). Abuse (adjusted 
rate ratio [ARR]=1.52, 95% CI=1.10-2.10), probable misuse (ARR=1.98, 95% CI=1.46-2.67), and 
possible misuse (ARR=1.76, 95% CI=1.48-2.09) were associated with significantly more events of 
opioid medication overdose compared to those without.
Conclusions—Claims-based measures can be employed by health systems to identify 
individuals at-risk of overdose who can be targeted for restrictions on opioid prescribing, 
dispensing, or referral to treatment.
Keywords
Opioid medication overdose; health claims; opioid medication misuse and abuse
Introduction
Prescription opioid overdose (poisonings) and mortality have risen at alarming rates since 
2000,1 with fatal overdoses now at 44 per day.2 This epidemic has spurred a national call to 
action, with the White House urging health systems to invest in surveillance, prevention, and 
treatment.3,4 Opioid surveillance and overdose prevention efforts, such as prescription 
monitoring and lock-in programs, rely on the ability of payers and healthcare systems to 
accurately identify patients at-risk of opioid overdose. Commonly used measures in opioid 
medication use and overdose surveillance include indicators of exposure, such as morphine 
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milligram equivalents (MME).5-12 Yet, MME does not differentiate patient from prescribing 
behavior. There are, unfortunately, no standard indicators for measuring overdose risk in 
administrative data routinely available to these stakeholders.13
Researchers and health systems have employed various conceptual and operational 
definitions to measure non-medical use of prescription opioids13-15 that could be beneficial 
for identifying overdose risk. The definition of non-medical use often hinges on motivation 
for use, whether the drug was prescribed for those using it, or opioid use disorder 
symptoms.14 One promising operational definition identifies non-medical use based on 
addiction diagnoses. White et al.16 and Rice et al.17 developed and demonstrated criterion 
validity13 for a diagnosis-basedmeasure of what they labeled ‘abuse’ constituted by 
individuals receiving an opioid prescription while simultaneously having an opioid use 
disorder or poisoning diagnosis. Other researchers have identified opioid utilization patterns 
consistent with what is labeled ‘misuse.’ Sullivan et al.18 developed and demonstrated 
criterion validity13 for a utilization-based measure of misuse that combines numbers of 
prescribers from which patients received opioid prescriptions, numbers of pharmacies where 
prescriptions were filled, and days-supplied of short- and long-acting opioid medications.
It is unknown whether these tools designed for defining non-medical use predict risk of 
overdose. We sought to determine whether these measures, which rely on diagnoses and 
prescription fill behaviors, were associated with overdose. Using Pennsylvania (PA) 
Medicaid data, we constructed a heterogeneous cohort of patients initiating prescription 
opioid treatment. While claims data do not permit us to capture care for which cash was 
paid16-18 medication diversion outside of prescriber/pharmacy reimbursement systems19 and 
likely underestimate the prevalence of non-medical use of opioids—our findings provide an 
important advancement to the field by testing these relationships and informing data-driven 
health system efforts to target prevention and intervention for individuals with overdose risk. 
Moreover, some systems have recently implemented policies restricting access to opioids 
based on dosage or number of prescription fills.20,21 The measures we examine could offer 
valuable information that may augment existing approaches.
Methods
Design and Cohort
This investigation was a longitudinal retrospective cohort study using PA Medicaid data 
from 2007-2012, a state with the 8th highest overdose rate in the US and opioid prescribing 
above national averages.1,22 We obtained study data from the PA Department of Human 
Services. Based on Medicaid enrollment data, we excluded individuals from our cohort who 
were non-PA residents, were <18, or were dual-eligible for Medicare (due to age >64 or 
disability) because of inability to capture medication use. Using pharmacy claims, we then 
identified all individuals with a new prescription fill for ≥1 oral, transdermal, or submucosal 
opioid medication. Using medical claims, we excluded patients with any cancer diagnosis 
and individuals receiving long-term care for ≥90 days and/or hospice services (online-only 
Figure 1).
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Given our goal was to identify whether the diagnosis-based abuse measure and/or 
utilization-based misuse measure predicted overdose, we constructed opioid treatment 
episodes based on initiation of opioid use rather than including all prevalent users. The index 
event was an opioid fill preceded by a 6-month period wherein patients had continuous 
enrollment in Medicaid. We also excluded those having any medical claims for opioid 
medication fills, diagnoses of opioid use disorders, or overdose during the 6 months prior to 
the index opioid prescription. We determined episodes would end when there was a 6-month 
gap between fills. A 6-month gap in fills to end episodes was selected given this timing 
follows previous conventions in behavioral health literature.23 Furthermore, because our key 
independent variables (described below) require at least 6 months to accrue necessary 
opioid-related behaviors to begin to construct, a 6-month gap demarcates a reasonable end of 
the opioid exposure that could be used to identify these risks of interest.24 Some enrollees 
had multiple opioid treatment episodes, and we included all episodes in our analyses 
meeting criteria (online-only Figure 2). This study was designated exempt by the University 
of Pittsburgh Institutional Review Board.
Variables
Our overdose outcome followed previously published methods for identifying prescription 
opioid overdose using International Classification of Disease, 9th edition (ICD-9)25 codes in 
health claims data.26 We included: 965.00 (opium poisoning), 965.02 (methadone 
poisoning), 965.09 (opiate poisoning-not elsewhere classified), E.850.1 (accidental 
methadone poisoning), and E.850.2 (accidental opioid poisoning-not elsewhere classified. 
See online-only Table 1 for ICD-10 crosswalk).26 These codes were dichotomized, 
indicating patients had experienced an overdose or not (no overdose=0, overdose=1) during 
opioid treatment. Within the Medicaid claims data analyzed for this project, these codes 
capture: 1) non-fatal overdoses resulting in emergency department visits, hospitalization, or 
other medical care and 2) fatal overdoses resulting in emergency department visits or 
hospitalization. We do not, however, capture overdoses occurring outside of hospitals or 
other healthcare settings. Although evidence suggests for every fatal overdose there are 
20-30 non-fatal events,27 we cannot assess what proportion of overdose events are captured 
in our data.
Our indicators of opioid overdose risk followed previously published 
conceptualizations.16-18 The diagnosis-based indicator of abuse, called abuse hereafter, 
followed the White et al.16 and Rice et al.17 operationalization in that patients with an opioid 
use disorder (ICD-9 304.0, 304.00, 304.01, 304.02, 304.03, 304.7, 304.70, 304.71, 304.72, 
304.73, 305.5, 305.50, 305.51, 305.52, 305.53. See online-only Table 1 for ICD-10 
crosswalk) while possessing a prescription opioid medication were classified as positive for 
abuse (no abuse=0, abuse=1). Our use of the term “abuse” is not necessarily consistent with 
a clinical diagnosis using established criteria in the Diagnostic and Statistical Manual of 
Mental Disorders (DSM) but rather a construct used in the literature that can be discretely 
measured in administrative data. This current operationalization of abuse was modified 
slightly from the previously published in that poisoning codes were not included given their 
presence in the overdose outcome indicator (i.e., ICD-9 965.00, 965.02, 965.09). To avoid 
including diagnoses of opioid use disorder recorded during an overdose event, we required 
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opioid use disorder claims to be present ≥7 days preceding overdose events (mean days 
between first abuse event and first overdose event was 297, SD=293.2, results not shown).
The utilization-based misuse indicator, called misuse hereafter, followed Sullivan et al.'s18 
operationalization. This indicator is calculated by coding number of opioid prescribers (≤2 
prescribers=0, 3-4 prescribers=1, ≥5 prescribers=2), number of pharmacies used for 
medication filling (≤2 pharmacies=0, 3-4 pharmacies=1, ≥5 pharmacies=2), days supplied of 
short-acting opioids, and days of supply of long-acting opioids (≤185 days=0, 186-240 
days=1, >240 days=2) over 6-month periods. Six-month periods were subsequently 
summated into 1 year periods, as in the previous study.18 Total scores were divided into 3 
categories: no misuse (0-1), possible misuse (2-4), and probable misuse (≥5). Our 
longitudinal design contains some episodes spanning multiple years and some patients 
having varying levels of no, possible, and probable misuse within a single continuous opioid 
treatment episode. Therefore, we assigned patients’ highest individual misuse score within 
analyses for those with multiple misuse categorizations within-episode. In addition, a quarter 
(n=147,057) of patient records in our dataset had missing prescriber identification numbers 
for pharmacy claims. Therefore, we could not calculate the misuse indicator for these 
individuals (see Analysis section for methods of handling missing data).
Categorical daily MME was included to compare its association with overdose to abuse and 
misuse given its prevalent use within the opioid medication overdose and non-medical use 
literature.5-12 MME was constructed by converting total within-episode opioid supply into 
morphine equivalents, dividing by days supplied, and coding into 4 levels (≥100 MME/day, 
50-<100 MME/day, 20-<50 MME/day, <20 MME/day).28 Level of MME/day varied by 
individual across episodes.
Covariates were measured in each person-episode's baseline period (i.e., 6 months prior to 
the index opioid fill) and included age (18-29, 30-39, 40-49, 50-64 years), sex, race/ethnicity 
(white, minority), initial Medicaid eligibility category (General Assistance, Supplemental 
Security Income, Temporary Assistance for Needy Families, Waiver) with some enrollees 
changing type within episode, Medicaid plan type (fee-for-service, managed care 
organization), and urban/rural living location (Rural-Urban Continuum Codes29,30). We 
included measures of comorbidity as covariates (online-only Table 2), including alcohol use 
disorders (abuse/dependence), non-opioid drug use disorders (abuse/dependence), individual 
mental health disorders (adjustment, anxiety, mood, personality, miscellaneous), individual 
pain diagnoses (back, neck, arthritis/joint, headache/migraine), and HIV/AIDS.31 We 
likewise included a modified Elixhauser comorbidity index with conditions removed that 
were included as separate covariates. We also included methadone maintenance (procedure 
codes H0020/J1230), buprenorphine use (forms approved for opioid use disorder), 
benzodiazepine use, and muscle relaxant use. Methadone maintenance and buprenorphine 
use were captured in the periods following the index fill but before the overdose. We 
included having ≥1 emergency department visits as a health services indicator. All covariates 
were categorical except the comorbidity index, which was a count measure, and age and 
length of episodes were ordinal.
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To summarize individual demographic and health indicators within our cohort, we calculated 
unduplicated patient-level univariable statistics. To report overdose, abuse, misuse, and 
MME/day, we calculated episode-level univariable statistics. To assess the relationship 
between overdose and (a) abuse, (b) misuse, and (c) MME/day, we estimated an episode-
level generalized linear model with general estimating equation (GEE) using log link 
function and Poisson distribution where follow-up time was treated as an offset term.32 
Overdose events were modeled as the dependent variable across time and abuse, misuse, and 
MME/day were included as independent variables—each occurring in time order prior to 
overdose. The GEE allowed us to cluster episodes within patient, accounting for within 
person correlation. The exchangeable correlation matrix was employed to account for 
standard error correlation. To ease interpretation, we also report adjusted predicted rate of 
overdose events per person days for abuse, misuse, and MME/day from the model. Analyses 
were conducted using SAS 9.4.33 Mentioned above, prescriber identification number was 
missing for some cohort members not allowing us to create the misuse variable for these 
individuals. To account for this missing information and reduce bias associated therewith, 
we employed the inverse probability weighting (IPW) method. In the IPW method, we first 
built a logistic regression model of nonmissing/missing prescriber identification number as 
the outcome variable, and abuse, misuse, and all other demographic/health indicators (listed 
above) as predicting covariates. For each patient with nonmissing prescriber identification 
number, a weight was then calculated as the inverse of the estimated probability from the 
fitted logistic regression. These weights were incorporated into the main overdose model. A 
nonweighted main overdose model (complete case analysis) was also fit for comparison. The 
results using these approaches were consistent.
Results
Descriptive and Univariable Results
Table 1 displays cohort demographics measured at the patient-level (online-only Table 3 for 
comorbid health condition summary statistics). A total of 372,347 Medicaid enrollees were 
included in our cohort. Individuals in the cohort had a mean of 1.6 (SD=0.9) episodes, and 
the average follow up days for individuals within episode was 488.5 (SD=388.8. Online-
only Table 3).
Table 2 displays episode-level results (N=583,013) and unadjusted overdose prevalence. We 
detected 1,270 (0.2%) total opioid overdose events across all opioid treatment episodes. 
Figure 1 displays the rate of overdose among patients by number of opioid treatment 
episodes, which ranged from 0.17% for patients with 1 episode up to 0.92% for those with 
≥7 episodes.
Table 2 also displays unadjusted frequencies of abuse, misuse, and MME/day by overdose. 
We detected a total of 19,019 (3.3%) instances of abuse prior to overdose. The rate of opioid 
overdose was significantly higher among those with abuse (1.5%) compared to those without 
(0.2%, p<0.001). A relatively small share of opioid treatment episodes were marked by 
misuse before overdose, with 2,880 (0.5%) having probable misuse and 20,893 (3.6%) with 
Cochran et al. Page 6













possible misuse (results not shown). Overdose was significantly higher among those with 
probable (1.8%) and possible (0.9%) misuse compared to those without (0.2%, p<0.001).
Multivariable Results
In the multivariable model (Table 3), the strongest opioid consumption overdose indicators 
were probable misuse (adjusted rate ratio [ARR]=1.98, 95% CI=1.46-2.67) and possible 
misuse (ARR=1.76, 95% CI=1.48-2.09), compared to no misuse. Individuals who had 
opioid medication abuse had a 52% higher rate overdose (95% CI=1.10-2.10) compared to 
those without. Consuming ≥100 MME/day was associated with higher a rate overdose 
compared to those with <20 MME/day (ARR=1.96, 95% CI=1.36-2.83). Figure 2 reports 
adjusted rates for overdose per average person days (where 488.5 was the average number of 
follow-up days for subjects in the cohort). The predicted number of overdose events based 
on the multivariable results was 0.46 per average person days among those with abuse 
compared to 0.30 with no abuse. The rate of overdose was 0.48 among those with probable 
misuse and 0.43 among those with possible misuse, compared to 0.24 among those with no 
misuse. Individuals with ≥100 MME/day had a predicted overdose rate of 0.59 compared to 
0.29-0.37 for those at lower doses.
Additionally, methadone agonist therapy claims (ARR=1.89, 95% CI=1.40-2.56) and having 
≥1 emergency department visits were associated with higher rates for overdose (ARR=1.64, 
95% CI=1.40-1.92). Alcohol use disorders (ARR=1.54, 95% CI=1.22-1.94) and non-opioid 
drug use disorders (ARR=1.52, 95% CI=1.22-1.89) were associated with higher rates of 
overdose. Any benzodiazepine use (ARR=1.42, 95% CI=1.17-1.73), mood disorders 
(ARR=1.31, 95% CI=1.11-1.54), anxiety disorders (ARR=1.28, 95% CI=1.07-1.54), and 
any muscle relaxant use (ARR=1.25, 95% CI=1.02-1.53) were also associated with 
overdose.
Discussion
Our results show these claims-based measures of non-medical use of prescription opioids, 
abuse and misuse, were associated with some of the highest rates of overdose—even when 
adjusted for exposure of daily opioid dosages (MME/day). No previous studies, to our 
knowledge, have examined abuse and misuse indicators as predictors of overdose, 
particularly in a longitudinal cohort. These potential risk factors constructed with claims 
data can be measured by payers to identify individuals at-risk for opioid overdose and 
potentially better differentiate patient from prescribing behavior compared to other 
measures, such as daily dosages.
Diagnosis-based Abuse and Utilization-based Misuse
One of the strongest indicators associated with overdose was abuse. Active management of 
opioid prescriptions among patients with opioid use disorders must be a continual priority 
for practitioners.34-36 Health systems should actively identify these patients for intervention 
and referral. Furthermore, this measure requires less data to construct and is conceptually 
simpler than the misuse indicator and could be amenable to plan/programs seeking to 
employ more easily implemented validated metrics of overdose risk.
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Misuse was also associated with overdose and has the potential to be valuable for health 
systems to monitor potentially modifiable behaviors and/or filling patterns. This indicator 
encompasses patient prescription seeking behaviors (e.g., “shopping”), including number of 
prescribers and pharmacies where opioids were filled and long- and short-acting opioids. 
Prescription claims do not necessarily lead to consumption, and certainly, absence of a fill 
does not necessarily reflect lack of use.19 Nevertheless, health systems (such as payers, 
prescription monitoring programs, which are active in nearly all US states) and pharmacy 
benefits managers could direct interventions at the components of the misuse indicator to 
reduce overdose risk. For example, systems could reduce or cap numbers of prescribers from 
whom patients receive medications or limit patients to filling prescriptions at a particular 
pharmacy through ‘lock-in’ programs.37 Promising data show success for these programs in 
reducing volume of medication prescribed, lowering costs, and increasing medication 
adherence.38 Lock-in programs are recommended by the Centers for Medicare and Medicaid 
Services as possible tools for improving monitoring and reducing diversion.39 Despite 
concerns in the field regarding restricting access to opioids for pain management,40 recent 
research has documented most heroin users engaged in non-medical use of prescription 
opioids prior to initiating heroin.41-42 This fact underscores the importance of better 
managing access to these medications to mitigate risk for transitioning from prescription 
opioids to heroin.
It is important to note that despite the relationships evident between overdose and abuse and 
misuse, many opioid treatment episodes with overdose events did not have these conditions 
present. On a population level, these indicators can be important tools for health systems to 
identify overdose risk. Nevertheless, some individuals will not be identified using these 
metrics because, for instance, they obtain opioids outside the healthcare system, they have 
not been recognized as suffering from an opioid use disorder, or other reasons. To 
complement claims-based measures such as those we examine, additional data sources from 
electronic health record systems and other sources could be explored as this research 
continues. Given lags in claims submission (greater than 6 months for some healthcare 
providers), more “real-time” data from electronic health records and other sources could be 
examined in order to facilitate more rapid risk identification.
Other Risk Factors
Additional risk factors were identified in our analyses. The larger the number of opioid 
treatment episodes was associated with higher overdose rates. Health systems have the 
capability to monitor patients regularly going on and off of opioid medications. Moreover, 
concomitant prescriptions of other psychoactive/high abuse potential medications were 
associated with some of the highest odds for overdose compared to other covariates. Such 
prescribing practices should be the target of formulary management tools that, if triggered, 
would initiate system warnings, prior authorization, and/or medication review. We 
recognize, however, our design intentionally excluded previous overdose in order to create a 
clean baseline period. Given evidence showing that non-fatal overdose is a risk factor for 
subsequent overdose,43 health systems may consider incorporating this information into 
surveillance systems.
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A number of other mental, behavioral, and physical health conditions were related to 
increased risk for overdose. The relationship between co-occurring health conditions and 
overdose has been documented previously8,44,45 and calls for multidimensional monitoring 
by health systems.
Limitations
Our study has some important limitations. Despite advantages in our study, which include 
PA having high opioid use and overdose rates,1,22 the PA Medicaid program being among 
the largest in the country, and these analyses containing both fee-for-service and managed 
care claims—46-48 the results herein represent one state in the northeastern US. Furthermore, 
Medicaid populations tend to predominantly consist of Temporary Assistance to Needy 
Families recipients. Thus, our findings may not generalize to other regions or populations. 
We note specifically that we lack prescription data on the elderly dually enrolled in 
Medicare. Furthermore, our overdose measure was based on ICD-9 codes from inpatient or 
emergency department claims. Therefore, we do not capture overdoses occurring outside of 
hospital. We also may both underestimate and overestimate misuse of prescription opioids 
using claims data because we are unable to measure diversion of opioid medications. Yet, 
the constellation of factors constituting the abuse and misuse indicators have been generally 
documented to be associated with unhealthy and problematic consumption patterns5,7,8,16-18 
and warrant observation and possible scrutiny. We also recognize opioid use disorders are 
likely underdiagnosed and under-coded within claims.49 Our claims-based measures of 
medication use and diagnoses may have poor sensitivity and specificity due to the nature of 
substance abuse coding and prescription opioid diversion. Nevertheless, our findings show 
strong associations between several claims-based risk factors and overdose—a first step in 
establishing a paramount line of scientific inquiry. Prospective research should seek to 
further develop and refine overdose risk prediction tools. Finally, we acknowledge the 
association between overdose and methadone maintenance therapy in our findings (ARR: 
1.89, 95% CI=1.40-2.56). To examine the contribution methadone maintenance makes 
within the overdose outcome model, we removed this indicator and re-estimated the model. 
The only substantive difference was the ARR between abuse and overdose increased from 
1.52 (95% CI=1.10-2.10) to 1.86 (95% CI=1.38-2.50), suggesting some variance accounted 
for by abuse is shared by methadone maintenance. These results do not indicate engaging in 
methadone treatment is in itself a risk for overdose but may contribute to some degree. Our 
future research will seek to better understand this relationship in order to provide 
recommendations to the field on how to maximize safety and benefit for these individuals.
Conclusion
Health systems possess rich data resources with the potential to be employed for enhancing 
national efforts in monitoring and targeting interventions against opioid overdose. Our 
findings indicate the importance of systems identifying those at-risk of overdose and 
working to implement policies and programs to protect patient health. Our findings should 
be replicated within other Medicaid and commercial plans, as well as they should be 
prospectively examined. Confirming these results would provide added support for systems 
to respond to urging from the White House to work and invest in integrating surveillance 
infrastructure into claims management systems. Indeed, the same technologies that 
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pharmacists utilize to verify insurance benefits could be programmed with abuse and misuse 
indicators that would alert pharmacists at point of service. If patients’ cumulative behaviors 
triggered misuse alerts, for instance, these could be followed with patient-focused 
medication therapy management interventions50 and naloxone referrals. Payers similarly 
could regularly run abuse and misuse algorithms that once triggered would initiate system-
level interventions (e.g., lock-in, prior authorization). Such efforts could help curb these 
behaviors and safeguard patient health.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
Funding
Drs. Cochran, Donohue, Gordon, and Gellad are supported by a grant from the Centers for Disease Control and 
Prevention (U01CE002496). This work was also supported in part by an intergovernmental agreement between the 
Pennsylvania Department of Human Services and the University of Pittsburgh.
References
1. Rudd, R., Aleshire, N., Zibbell, J., Gladden, M. Increases in Drug and Opioid Overdose Deaths — 
United States, 2000–2014. Centers for Disease Control and Prevention; Atlanta, GA: 2015. 
2. Centers for Disease Control and Prevention. [July 16, 2015] Prescription Drug Overdose Data: 
Deaths from Prescription Opioid Overdose. 2015. http://www.cdc.gov/drugoverdose/data/
overdose.html.
3. White House. Obama Administration Announces Public and Private Sector Efforts to Address 
Prescription Drug Abuse and Heroin Use [press release]. Office of the Press Secretary; Washington 
DC: 2015. 
4. Haegerich TM, Paulozzi LJ, Manns BJ, Jones CM. What we know, and don’t know, about the 
impact of state policy and systems-level interventions on prescription drug overdose. Drug Alcohol 
Depend. 2014; 145:34–47. [PubMed: 25454406] 
5. Logan J, Liu Y, Paulozzi L, Zhang K, Jones C. Opioid prescribing in emergency departments: the 
prevalence of potentially inappropriate prescribing and misuse. Med Care. 2013; 51:646–653. 
[PubMed: 23632597] 
6. Mack KA, Zhang K, Paulozzi L, Jones C. Prescription practices involving opioid analgesics among 
Americans with Medicaid, 2010. J Health Care Poor Underserved. 2015; 26:182–198. [PubMed: 
25702736] 
7. Liu Y, Logan JE, Paulozzi LJ, Zhang K, Jones CM. Potential misuse and inappropriate prescription 
practices involving opioid analgesics. Am J Manag Care. 2013; 19:648–665. [PubMed: 24304213] 
8. Bohnert ASB, Valenstein M, Bair MJ, et al. Association between opioid prescribing patterns and 
opioid overdose-related deaths. JAMA. 2011; 305:1315–1321. [PubMed: 21467284] 
9. Paulozzi LJ, Strickler GK, Kreiner PW, Koris CM. Controlled Substance Prescribing Patterns--
Prescription Behavior Surveillance System, Eight States, 2013. Morbidity and mortality weekly 
report. Surveillance summaries. 2015; 64:1–14.
10. Dasgupta N, Funk MJ, Proescholdbell S, Hirsch A, Ribisl KM, Marshall S. Cohort Study of the 
Impact of High-dose Opioid Analgesics on Overdose Mortality. Pain Med. 2015 [Epub ahead of 
print]. 
11. Gwira Baumblatt JA, Wiedeman C, Dunn JR, Schaffner W, Paulozzi LJ, Jones TF. High-risk use by 
patients prescribed opioids for pain and its role in overdose deaths. JAMA Intern Med. 2014; 
174:796–801. [PubMed: 24589873] 
Cochran et al. Page 10













12. Dunn KM, Saunders KW, Rutter CM, et al. Opioid prescriptions for chronic pain and overdose: a 
cohort study. Ann Intern Med. 2010; 152:85–92. [PubMed: 20083827] 
13. Cochran G, Woo B, Lo-Ciganic W-H, Gordon AJ, Donohue JM, Gellad WF. Defining nonmedical 
use of prescription opioids within health care claims: a systematic review. Subst Abus. 2015; 
36:192–202. [PubMed: 25671499] 
14. Barrett SP, Meisner JR, Stewart SH. What constitutes prescription drug misuse? Problems and 
pitfalls of current conceptualizations. Curr Drug Abuse Rev. 2008; 1:255–262. [PubMed: 
19630724] 
15. Compton WM, Volkow ND. Abuse of prescription drugs and the risk of addiction. Drug Alcohol 
Depend. 2006; 83(Suppl 1):S4–7. [PubMed: 16563663] 
16. White AG, Birnbaum HG, Schiller M, Tang J, Katz NP. Analytic models to identify patients at risk 
for prescription opioid abuse. Am J Manag Care. 2009; 15:897–906. [PubMed: 20001171] 
17. Rice JB, White AG, Birnbaum HG, Schiller M, Brown DA, Roland CL. A Model to Identify 
Patients at Risk for Prescription Opioid Abuse, Dependence, and Misuse. Pain Medicine. 2012; 
13:1162–1173. [PubMed: 22845054] 
18. Sullivan MD, Edlund MJ, Fan M-Y, Devries A, Brennan Braden J, Martin BC. Risks for possible 
and probable opioid misuse among recipients of chronic opioid therapy in commercial and 
Medicaid insurance plans. The TROUP Study Pain. 2010; 150:332–339. [PubMed: 20554392] 
19. Substance Abuse and Mental Health Services Administration. Results from the 2013 National 
Survey on Drug Use and Health: Summary of National Findings. Substance Abuse and Mental 
Health Services Administration; Rockville, MD: 2014. 
20. Morden NE, Zerzan JT, Rue TC, et al. Medicaid prior authorization and controlled-release 
oxycodone. Med Care. 2008; 46(6):573–580. [PubMed: 18520311] 
21. Centers for Medicare and Medicaid Services. Best Practices for Addressing Prescription Opioid 
Overdoses, Misuse and Addiction. Centers for Medicare and Medicaid Services; Baltimore, MD: 
2016. 
22. Centers for Disease Control. Prevention Status Report 2013: Prescription Drug Overdose. Centers 
for Disease Control; Pennsylvania. Atlanta, GA: 2013. 
23. Melfi CA, Croghan TW. Use of claims data for research on treatment and outcomes of depression 
care. Med Care. 1999; 37(4 Suppl Lilly):As77–80. [PubMed: 10217395] 
24. Hornbrook MC, Hurtado AV, Johnson RE. Health Care Episodes: Definition, Measurement and 
Use. Med Care Res Rev. 1985; 42(2):163–218.
25. World Health Organization. International Statistical Classification of Diseases and Related Health 
Problems, 9th Edition (ICD-9). World Health Organization; Geneva: 2011. 
26. Unick GJ, Rosenblum D, Mars S, Ciccarone D. Intertwined epidemics: national demographic 
trends in hospitalizations for heroin- and opioid-related overdoses, 1993-2009. Plos One. 2013; 
8(2):e54496–e54496. [PubMed: 23405084] 
27. Darke S, Mattick RP, Degenhardt L. The ratio of non-fatal to fatal heroin overdose. Addiction. 
2003; 98(8):1169–1171.
28. Prescription Drug Monitoring Program training and Technical Assistance Center. Technical 
Assistance Guide No. 01-13, Calculating Daily Morphine, Milligram Equivalents. Brandeis 
University, The Heller School for Policy and Management; Boston, MA: 2013. 
29. United States Department of Agriculture. [October 3, 2014] Rural-Urban Continuum Codes. 2013. 
http://www.ers.usda.gov/data-products/rural-urban-continuum-codes/
documentation.aspx#.VC61zGddUrA.
30. Baldwin LM, Andrilla CH, Porter MP, Rosenblatt RA, Patel S, Doescher MP. Treatment of early-
stage prostate cancer among rural and urban patients. Cancer. 2013; 119:3067–3075. [PubMed: 
23765584] 
31. Sullivan MD, Edlund MJ, Fan M-Y, DeVries A, Brennan Braden J, Martin BC. Trends in use of 
opioids for non-cancer pain conditions 2000–2005 in Commercial and Medicaid insurance plans. 
The TROUP study Pain. 2008; 138:440–449. [PubMed: 18547726] 
32. SAS Institute Inc. SAS/STAT(R) 9.22 Users Guide. The GENMOD Procedure. SAS Institute Inc; 
Cary, NC: 2010. 
33. SAS 9.4 [computer program]. Cary; p. NC2013
Cochran et al. Page 11













34. Chang Y-P, Compton P. Management of chronic pain with chronic opioid therapy in patients with 
substance use disorders. Addict Sci Clin Pract. 2013; 8:21. [PubMed: 24341916] 
35. Savage SR, Kirsh KL, Passik SD. Challenges in Using Opioids to Treat Pain in Persons With 
Substance Use Disorders. Addict Sci Clin Pract. 2008; 4:4–25. [PubMed: 18497713] 
36. Nuckols TK, Anderson L, Popescu I, et al. Opioid prescribing: a systematic review and critical 
appraisal of guidelines for chronic pain. Ann Intern Med. 2014; 160:38–47. [PubMed: 24217469] 
37. Roberts AW, Skinner AC. Assessing the present state and potential of Medicaid controlled 
substance lock-in programs. J Manag Care Spec Pharm. 2014; 20:439–446c. [PubMed: 24761815] 
38. Centers for Disease Control and Prevention. Patient Review & Restriction Programs Lessons 
learned from state Medicaid programs. Centers for Disease Control and Prevention; Atlanta, GA: 
2012. 
39. Centers for Medicare and Medicaid Services. Drug Diversion in the Medicaid Program: State 
Strategies for Reducing Prescription Drug Diversion in Medicaid. Department of Health and 
Human Services, Centers for Medicare and Medicaid Services, Center for Program Integrity; 
Baltimore, MD: 2012. 
40. Alford DP. Opioid Prescribing for Chronic Pain — Achieving the Right Balance through 
Education. N Engl J Med. 2016; 374:301–303. [PubMed: 26816007] 
41. Cicero TJ, Ellis MS, Surratt HL, Kurtz SP. The changing face of heroin use in the United States: a 
retrospective analysis of the past 50 years. JAMA Psychiatry. 2014; 71:821–826. [PubMed: 
24871348] 
42. Cicero TJ, Ellis MS. Abuse-Deterrent Formulations and the Prescription Opioid Abuse Epidemic in 
the United States: Lessons Learned From OxyContin. JAMA Psychiatry. 2015; 72:424–430. 
[PubMed: 25760692] 
43. Hall AJ, Logan JE, Toblin RL, et al. Patterns of abuse among unintentional pharmaceutical 
overdose fatalities. JAMA. 2008; 300(22):2613–2620. [PubMed: 19066381] 
44. Webster LR, Cochella S, Dasgupta N, et al. An analysis of the root causes for opioid-related 
overdose deaths in the United States. Pain Med. 2011; 12(Suppl 2):S26–S35. [PubMed: 21668754] 
45. Centers for Disease Control and Prevention. Overdose deaths involving prescription opioids among 
Medicaid enrollees- Washington, 2004-2007. MMWR. Morbidity And Mortality Weekly Report. 
2009; 58:1171–1175. [PubMed: 19875978] 
46. Centers for Disease Control and Prevention. Health, United States 2012: With Special Feature on 
Emergency Care. Centers for Disease Control; Hyattsville, MD: 2013. 
47. Dartmouth. [March 8, 2014] The Dartmouth Atlas of Health Care. 2014. http://
www.dartmouthatlas.org/.
48. Pating DR, Miller MM, Goplerud E, Martin J, Ziedonis DM. New systems of care for substance 
use disorders: treatment, finance, and technology under health care reform. Psychiatr Clin North 
Am. 2012; 35:327–356. [PubMed: 22640759] 
49. Kim HM, Smith EG, Stano CM, et al. Validation of key behaviourally based mental health 
diagnoses in administrative data: suicide attempt, alcohol abuse, illicit drug abuse and tobacco use. 
BMC Health Serv Res. 2012; 12(1):1–9. [PubMed: 22214259] 
50. Viswanathan M, Kahwati LC, Golin CE, et al. Medication therapy management interventions in 
outpatient settings: A systematic review and meta-analysis. JAMA Intern Med. 2015; 175(1):76–
87. [PubMed: 25401788] 
Cochran et al. Page 12













Figure 1. Overdose Rate Based on Number of Opioid Treatment Episodes per Person 
(N=372,347) a
This figure contains overdose rates for patients within the cohort by the number of individual 
opioid treatment episodes they have.
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Figure 2. Predicted Overdose Rate with 95% Confidence Intervals by Abuse, Misuse, and Daily 
Morphine Milligram Equivalents (MMEs/day) Adjusted for All Covariates and Offset by Log 
Length of Episode a,b
This figure contains the adjusted predicted overdose rates for opioid abuse, misuse, and daily 
morphine milligram equivalents.
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Table 1






    White 203,985 (54.8)
    Black 108,529 (29.2)
    Hispanic 45,241 (12.1)
    Other 14,592 (3.9)
Urban living area 317,197 (85.2)
Type of eligibility
    General Assistance 42,802 (11.5)
    Supplemental Security Income 94,488 (25.4)
    Temporary Assistance to Needy Families 220,650 (59.2)
    Waiver 14,407 (3.9)
Type of health plan
    Managed care 287,399 (77.2)
    Fee-for-service 84,948 (22.8)
a
Mean (standard deviation)
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Table 2
Potential Risk Factors for Opioid Medication Overdose (N=583,013)
Overdose, n (%)
Potential Risk Factors Yes No p
Total
a 1,270 (0.2) 581,743 (99.8)
Abuse
    Yes 278 (1.5) 18,813 (98.5) <.001
    No 992 (0.2) 562,930 (99.8)
Categorical misuse
    Probable misuse 51 (1.8) 2,829 (98.2)
    Possible misuse 180 (0.9) 20,713 (99.1) <.001
    Missing misuse
b 236 (0.2) 145,406 (99.8)
    No misuse 803 (0.2) 412,795 (99.8)
Categorical MEM, MEM/day
    <20 200 (0.2) 91,150 (99.8)
    20-49.9 810 (0.2) 390,772 (99.8) <.001
    50-99.9 190 (0.2) 84,337 (99.8)
    ≥100 70 (0.5) 15,484 (99.5)
a
Counted for all eligible episodes.
b
145,642 (25.0%) records missing provider ID missing in the claim files.













Cochran et al. Page 17
Table 3
Generalized Linear Model Estimates and Adjusted Rate Ratios for Overdose
a
Predictors Estimate (SE) ARR (95% CI) P Value
Opioid use risk factors
Diagnosis-based abuse 0.42 (0.17 ) 1.52 (1.10-2.10 ) .01
Utilization-based misuse (reference=No misuse)
    Possible misuse 0.56 (0.09 ) 1.76 (1.48-2.09 ) <.001
    Probable misuse 0.68 (0.15 ) 1.98 (1.46-2.67 ) <.001
Morphine milligram equivalents/day (reference=<20MMEs/day)
    20-49.9 0.02 (0.10 ) 1.02 (0.85-1.23 ) .83
    50-99.9 0.23 (0.13 ) 1.26 (0.97-1.63 ) .08
    ≥100 0.67 (0.19 ) 1.96 (1.36-2.83 ) <.001
Demographics
Age, y −0.16 (0.04 ) 0.86 (0.79-0.93 ) <.001
Female −0.46 (0.08 ) 0.63 (0.54-0.74 ) <.001
White 0.44 (0.12 ) 1.55 (1.22-1.96 ) <.001
Urban living area 0.57 (0.12 ) 1.78 (1.39-2.27 ) <.001
Medicaid enrollment and eligibility
Fee-for-service −0.60 (0.25 ) 0.55 (0.34-0.90 ) .02
Type of eligibility (reference=TANF
b
)
    General assistance 0.06 (0.11 ) 1.06 (0.85-1.32 ) .62
    Supplemental Security Income 0.08 (0.08 ) 1.08 (0.92-1.27 ) .33
    Waiver −0.56 (0.28 ) 0.57 (0.33-0.98 ) .04
Comorbidities and health service use
Alcohol abuse/dependence 0.43 (0.12 ) 1.54 (1.22-1.94 ) <.001
Drug abuse/dependence 0.42 (0.11 ) 1.52 (1.22-1.89 ) <.001
Adjustment disorders 0.18 (0.18 ) 1.20 (0.84-1.71 ) .32
Anxiety disorders 0.25 (0.09 ) 1.28 (1.07-1.54 ) .01
Mood disorders 0.27 (0.08 ) 1.31 (1.11-1.54 ) .001
Personality disorders 0.23 (0.24 ) 1.26 (0.79-2.01 ) .33
Miscellaneous mental health disorders −0.18 (0.16 ) 0.83 (0.61-1.15 ) .26
Back pain 0.04 (0.10 ) 1.04 (0.86-1.26 ) .70
Neck pain −0.09 (0.13 ) 0.91 (0.71-1.17 ) .46
Arthritis /joint pain −0.10 (0.08 ) 0.90 (0.77-1.06 ) .22
Headache/migraine pain −0.22 (0.17 ) 0.81 (0.58-1.12 ) .20
HIV/AIDS 0.06 (0.29 ) 1.06 (0.60-1.87 ) .84
Emergency department visits 0.49 (0.08 ) 1.64 (1.40-1.92 ) <.001
Elixhauser comorbidity index −0.05 (0.04 ) 0.95 (0.88-1.03 ) .23
Other medication use
Any muscle relaxant use 0.22 (0.10 ) 1.25 (1.02-1.53 ) .03
Any benzodiazepine use 0.35 (0.10 ) 1.42 (1.17-1.73 ) <.001
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Predictors Estimate (SE) ARR (95% CI) P Value
Methadone maintenance 0.64 (0.15 ) 1.89 (1.40-2.56 ) <.001
Buprenorphine for opioid use disorder −0.41 (0.17 ) 0.66 (0.47-0.93 ) .02
a
Poisson regression with log link function is used. Model is offset by log days of follow-up to account for individual exposure to opioid treatment 
within episode.
b
Temporary Assistance to Needy Families.
Med Care. Author manuscript; available in PMC 2018 March 01.
